アレンドロン酸ナトリウム

動物種別の用量

用量は獣医療従事者向けの臨床リファレンスです。必ず最新の添付文書と個々の患者で確認してください。

投与経路

禁忌

• Esophageal abnormalities (e.g., strictures, achalasia) that delay esophageal emptying
• Inability to stand or sit upright for 30 minutes post-administration (human guideline; veterinary relevance is managed via water chasers/activity)
• Severe renal dysfunction (Creatinine Clearance < 35 mL/min)
• Known hypersensitivity to alendronate or other bisphosphonates

有害事象

• Upper GI irritation and erosions
• Esophageal stricture or ulceration
• Vomiting
• Inappetence
• Jaw osteonecrosis (rare but documented in humans)
• Musculoskeletal pain
• Hypocalcemia (with overdose)
• Hypophosphatemia (with overdose)

薬物相互作用

• Aspirin · Increased risk of upper GI adverse effects and erosions.
• Calcium-containing oral products or food · Likely to significantly decrease the already low oral bioavailability of alendronate.
• Ranitidine (IV) · Increased oral alendronate bioavailability two-fold in a human study.
• NSAIDs · Humans taking NSAIDs with alendronate had no higher rates of GI adverse reactions than when NSAIDs were used with placebo, though caution is still advised. · moderate
• Antacids (Aluminum, Magnesium, Calcium) · Significantly decreases alendronate absorption · major
• Iron supplements · Decreases alendronate absorption · major

モニタリング

• Serum ionized calcium
• Serum phosphorus
• Serum potassium and sodium
• Signs of GI adverse effects (excessive salivation, regurgitation, dysphagia, inappetence)

過量投与

**Toxicity Profile:** No lethality was observed in dogs receiving doses up to 200 mg/kg. Lethality in rodents occurs at >550 mg/kg. **Clinical Signs of Overdose:** Hypocalcemia, hypophosphatemia, and severe upper GI reactions (ulceration, erosions). **Treatment:** * **DO NOT induce vomiting** due to the risk of severe esophageal irritation. * Administer **oral antacids or milk** immediately to bind the drug and prevent systemic absorption. * Monitor serum calcium and phosphorus levels closely. * Provide supportive care as needed.